Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of the best hot stocks to invest in. On October 8, Guggenheim initiated coverage of Olema Oncology with a Buy rating and $20 price target. The firm views Olema as the top biotech for selective estrogen receptor degrader/SERD breast cancer drugs. Guggenheim cited its palazestrant as the most promising drug in a $10 billion market.

The company discovers and develops targeted therapies for breast cancer and beyond. A key highlight was the selection of a 90 mg once-daily dose of its lead product candidate, palazestrant (OP-1250), for Part 2 of the ongoing pivotal OPERA-01 Phase 3 monotherapy trial and for the planned pivotal OPERA-02 Phase 3 trial.

In Q2 2025, Olema reported a Net Loss of $43.8 million for the quarter, compared to a net loss of $30.4 million for Q2 2024. The increase in net loss was due to increased R&D spending related to the late-stage trials for palazestrant and the advancement of OP-3136.

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapies for women’s cancers.

While we acknowledge the potential of OLMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.